BMN 333
Peptide
Evidence outlook · registrational
Achondroplasia: registrational readout pending
No completed mid-stage readout is on record. Registrational readout expected around 2029-06.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
ASPEN NCT07441876 · Achondroplasia Registry: NCT07441876 | 2/3 | Phase 2: Predicted Annualized Growth Velocity (AGV) at Week 52 (based on AGV at Weeks 26, 39, and 52 [available cumulative data] (52 weeks); Phase 3: Annualized Growth Velocity (AGV) at Week 52 (52 weeks) 2029-06 | In progress: results expected 1 Jun 2029 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2/3 (1)
What this study did
Competitive landscape
This drug's own stage for Achondroplasia: Phase 2/3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| BMN 333: this drug | Phase 2/3 | Peptide | C-type natriuretic peptide (CNP) pathway | not yet graded | No reviewed efficacy summary in this indication | |
| Vosoritide (VOXZOGO) | Approved | Peptide | Natriuretic peptide receptor B (NPR-B) | Reliable signal | NCT03197766: Change From Baseline in Annualized Growth Velocity (AGV) at Week 52 (At Baseline and Week 52): BMN 111 - 15 μg/kg 1.71 cm/year (95% CI 1.4 to 2.01) | Placebo 0.13 cm/year (95% CI -0.18 to 0.45) | |
| Lavengratinib | Phase 1/2 | Small molecule | FGFR2 / FGFR3 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow BMN 333 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.